Boston Scientific Launches Long-lasting ICD Line

Boston Scientific Corporation has launched a line of what it is calling the “longest lasting ICD  (implantable cardioverter defibrillator) in the world.” Some of the company’s existing ICDs have been upgraded to be a part of the new extended longevity (EL) line, including Dynagen EL and Inogen EL.

The first EL ICD was implanted at The University of Pittsburgh Medical Center (UPMC) by Samir Saba, M.D. The device features Enduralife battery technology designed to provide up to double the battery capacity of other ICDs. The EL ICD is projected to last nearly 12 years.

“Battery longevity has a direct impact on patient outcomes and the cost of care,” said Saba. “The EL ICD is an important advancement that can help minimize the frequency of avoidable replacement procedures to help reduce costs and the potential for replacement-related complications.”

According to Boston Scientific, the Enduralife battery ensures a longer ICD life than any other on the market, and also enables the ICDs to be smaller and slimmer. Increased device longevity can reduce the risk of infection and other complications over time, minimize out-of-pocket patient expenses for avoidable replacement procedures, and decrease other healthcare system costs associated with device therapy.

“Boston Scientific is proud to build upon the world’s most innovative ICD technology with the world’s smallest ICD, the world’s longest-lasting ICD and the world’s only subcutaneous ICD,” said Joe Fitzgerald, executive vice president and president, rhythm management. “By providing a device with greater battery capacity, physicians are now able to offer patients a longer lasting device and increased peace of mind, while administrators and payors have new options to more effectively manage healthcare costs and minimize unexpected complications.”